The FDA Granted Breakthrough Therapy Designation To Arrowhead Pharmaceuticals' Investigational Plozasiran As An Adjunct To Diet To Reduce Triglycerides In Adults With Familial Chylomicronemia Syndrome
Author: Benzinga Newsdesk | September 10, 2024 07:31am